Podcasts about bcma

Welcome to MuseNews, the BCMA's monthly museum sector news podcast. Each month we recap some of the latest breaking news, happenings, and announcements from museums, galleries, and heritage organizations across BC and beyond. April 2025 Stories: German artillery from First World War piece found buried at the PNE | Vancouver Sun New Terry Fox exhibit to open in the Canadian hero's hometown Reach Gallery Museum Abbotsford names new executive director Health-care providers to prescribe nature-inspired art for wellness at Vancouver Art Gallery Public access to Hudson Bay Company artifacts 'absolutely crucial,' Manitoba history prof says | CBC News Royal BC Museum sets a new course to share stories of Chinese migration - Greater Victoria News Museum of Vancouver's new CEO heralds conversations and community to engage visitors Britannia Mine Museum featured in latest episode of 'The Last of Us' If you have news you want to share on this program, please email us at bcma@museum.bc.ca

In this episode i'm going through the main card for UFC Miami. Volkanovoski beat the odds and father time to cap off one of the best UFC cards in a little while. this card really delivered. Lets talk about it. Enjoy,Kru LuckGym- www.LuckysMT.comPanteraBJJ -@PanteraJJ on Instagram

Join our host Lorenda and Dr. Will Atlas, Salmon Watershed Scientist, for a conversation about SalmonVision. In partnership with Indigenous communities, SalmonVision harnesses the power of AI for salmon monitoring and conservation. Explore rivers, waterways, and an ethical side of AI.  Resources: SalmonVision Wild Salmon Center Pacific Salmon Foundation First Nations harness power of AI to monitor wild salmon stocks in B.C. | CBC News Using AI to track salmon could be a ‘game-changer' | The Narwhal Restoring Indigenous fish weirs in B.C. | The Narwhal Artificial Intelligence, Meet Indigenous Fishing Technology - Wild Salmon Center  

In this episode I recap Christophe Broccoli winning the PFL amateur Kickboxing World championship, then taking a couple of fighters to a Muay thai tournaments the following week as well as my unboxing of stuff sent to me by Anaconda fightwear. Hope you enjoy!Kru LuckGym - www.LuckysMT.com BJJ - @PanterraJJ

Welcome to MuseNews, the BCMA's monthly museum sector news podcast. Each month we recap some of the latest breaking news, happenings, and announcements from museums, galleries, and heritage organizations across BC and beyond. March Stories:   West Van purchases Horseshoe Bay's Boathouse restaurant for new art museum  Summerland museum shares history Irish settler who helped develop the irrigation system - Penticton News - Castanet.net Kelowna Museum exhibit highlights Japanese Canadian dispossession The Whalers Washing House finally coming home - rabble.ca Possible 25 per cent tariff on books could kneecap local retailers  Horn heist: B.C. train museum gets railroaded by targeted thefts | CBC News Hundreds of items returned to First Nations in Vancouver Museum's ongoing repatriation process Outdoor exhibits reopening at Vancouver's Science World with gardening robot, more 

Peace people! Welcome back to another episode of the BCMA podcast. In this episode I talk about the uneventful UFC 313 where Pereira lost his belt to Ankalaev. The Legend Liam Harrison retires. Lastly I have to rant on the tate of martial arts a bit after seeing the crowds reaction to the Tate brothers when they arrived at UFC 313. Hope you enjoy. Kru LuckGym - www.LuckysMT.comInstagram - @Luckysmuaythai. @Panterabjj

Welcome to MuseNews, the BCMA's monthly museum sector news podcast. Each month we recap some of the latest breaking news, happenings, and announcements from museums, galleries, and heritage organizations across BC and beyond. February Stories: Nanaimo Art Gallery's new exhibit explores unexpected outcomes Barkerville Heritage Trust secures 7 more years running the historic site Surrey artist takes aim at Trump, Musk, Bezos with provocative paintings Exploration Place, BC Bob launch partnership for fundraiser ‘This is reclamation'; Tk'emlúps Kúkpi7 Casimir discusses historical designation for former residential school site Toddler's $4k offer ends apple pie bid war in support of Salmon Arm heritage site

Joe and Korey sit down with Chris Rippey, owner of Missouri Arborist Company, for the second and final part of this two part episode. In the second part Chris, a BCMA and RCA, shares some of his wildest stories from his career in the tree industry. If you would like to know more about Chris' company you can visit www.MissouriArborist.com for more information. Additionally if you or someone you know needs help with drugs or addition you can visit the following resources: https://www.samhsa.gov/find-help/helplines/national-helpline or https://www.usa.gov/substance-abuse  If you enjoyed the podcast please rate, review, subscribe and tell a fellow tree lover! Send your questions or topics you would like us to discuss to ⁠info@discoveringforestrypodcast.com⁠.Be sure to follow us on all your favorite social media platforms! Twitter/X: @DisForestryPod Instagram: @discovering_forestry Facebook: Discovering Forestry YouTube: @discoveringforestry6905 LinkedIn: Discovering Forestry PodcastMusic credit:⁠ Cool Tools Music Video - "Timber"⁠   ⁠Muzaproduction “Sport Rock Logo 1”⁠Hosted by: Joe Aiken & Korey LofyProduced by: Nico ManganielloArtwork by: Cara Markiewicz & Nico Manganiello

Featuring a slide presentation and related discussion from Dr Surbhi Sidana, including the following topics: Key clinical data of FDA-approved chimeric antigen receptor (CAR) T-cell therapies (0:00) Real-world evidence evaluating utility of CAR T-cell therapies in the clinic (8:08) Impact of prior BCMA-targeted treatment on CAR T-cell therapy efficacy (12:55) Investigational CAR T-cell therapies in clinical development (15:08) Incidence and management of toxicities associated with CAR T-cell therapy (18:21) CME information and select publications

Joe and Korey sit down with Chris Rippey, owner of Missouri Arborist Company, for part one of a two part episode. Chris, a BCMA and RCA, shares some of his wildest stories from his career in the tree industry. Chris and the guys also take an in depth look at the tree care industry and where to find the monetary value as someone working in the industry. If you would like to know more about Chris' company you can visit www.MissouriArborist.com for more information. Additionally if you or someone you know needs help with drugs or addition you can visit the following resources: https://www.samhsa.gov/find-help/helplines/national-helpline or https://www.usa.gov/substance-abuse  If you enjoyed the podcast please rate, review, subscribe and tell a fellow tree lover! Send your questions or topics you would like us to discuss to ⁠info@discoveringforestrypodcast.com⁠.Be sure to follow us on all your favorite social media platforms! Twitter/X: @DisForestryPod Instagram: @discovering_forestry Facebook: Discovering Forestry YouTube: @discoveringforestry6905 LinkedIn: Discovering Forestry PodcastMusic credit:⁠ Cool Tools Music Video - "Timber"⁠   ⁠Muzaproduction “Sport Rock Logo 1”⁠Hosted by: Joe Aiken & Korey LofyProduced by: Nico ManganielloArtwork by: Cara Markiewicz & Nico Manganiello

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:Early results with teclistamab combined with anti-CD38 therapyReal-world data with teclistamab including its use after other BCMA-targeted therapiesTalquetamab as bridging therapy to BCMA-targeted CAR T-cell therapyEvaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapyPresenter:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematologic MalignanciesConsultant, Division of HematologyProfessor of MedicineChair, Myeloma, Amyloidosis and Dysproteinemia GroupResearch Chair, Division of HematologyAssociate Chair for Research, Department of MedicineMayo ClinicRochester, MinnesotaLink to full program:https://bit.ly/40bjFCZ

In this episode I give a sincere thanks to evberyone that supported and we go down the rabbit hole to decide if there is a clear cut number two MMA promotion. Drop a comment below to let me know your thoughts. Hope you enjoy the show. Thank you all so much for listening along. Love you guys! Peace! Kru Luck www.LuckysMT.com @luckysmuaythai @Panterabjj

Welcome to MuseNews, the BCMA's monthly museum sector news podcast. Each month we recap some of the latest breaking news, happenings, and announcements from museums, galleries, and heritage organizations across BC and beyond. January Stories: Rebuilding Telegraph Cove: Community Mobilizes to Restore a Vital Economic Engine - West Coast NOW  Museum of Anthropology unveils first exhibit dedicated to the Nuxalk Nation | Georgia Straight Vancouver's source for arts, culture, and events Victoria museum display celebrates work of Japanese-Canadian photographer - Saanich News Northern B.C. museum honours pioneer female pilot from the early 1900s - Quesnel Cariboo Observer Museum of Northern BC commemorates 100 years with a reflective exhibit - Houston Today Unmasking heritage: the rise of women carvers on the North Coast - Houston Today Through sculpture, syilx Okanagan artist turns pictographs into towering 3D figures   If you have news you want to share on this program, please email us at bcma@museum.bc.ca

Welcome back! In this episode I talk about UFC 311 and how Merab used his cardio and his heart to defeat Umar Nurmagomedov. I touch on ONE Championship and the return of Marcelo Garcia. Finally I give my hot take for 2025. Hope you enjoy! Peace. Kru Luck Gym - www.LuckysMT.com Pantera Jiu Jitsu - @PanteraBJJ on Instagram

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Robert Orlowski from MD Anderson Cancer Center to discuss groundbreaking studies presented at ASH 2024 focused on multiple myeloma. We dived into four key studies: 1.⁠ ⁠AQUILA: Explore the impact of early intervention using daratumumab for smoldering myeloma, which showed improved progression-free survival (PFS) and overall survival (OS). 2.⁠ ⁠Dara Based Quad Therapy: We discuss a meta-analysis reaffirming the use of quadruplet therapy with anti-CD38 for newly diagnosed multiple myeloma as the standard of care. 3.⁠ CARTITUDE-4: study highlights the benefits of CAR-T therapy in earlier lines of treatment for patients with lenalidomide-refractory disease. 4.⁠ ⁠Role of IVIG with BCMA Bispecific Antibodies: Discover how IVIG can reduce infection rates and improve overall survival when used alongside BCMA-targeted therapies. Tune in for an insightful discussion that will enhance your understanding of the latest advancements in multiple myeloma treatment. Don't forget to check out our other episodes on CLL, myeloma, and lymphoma from ASH 2024! Subscribe to the Oncology Brothers for more updates and expert insights in oncology! Website: http://www.oncbrothers.com/  X/Twitter: https://twitter.com/oncbrothers  Contact us at info@oncbrothers.com

In this week's episode, we'll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who receive stem cell transplants, and a cell death process that may help account for increased thromboembolic risk in patients receiving cancer chemotherapy.Featured Articles:Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myelomaEmapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerismGSDME-mediated pyroptosis contributes to chemotherapy-induced platelet hyperactivity and thrombotic potential

In this short episode I catch you up on the long break and what we missed the last couple of weeks. Enjoy. Peace, Kru Luck www.LuckysMT.com @Luckysmuaythai --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

In this week's episode we'll learn more about how clonal hematopoiesis affects prognosis in patients with telomere biology disorders, consider recently uncovered molecular subtypes of extracutaneous juvenile xanthogranulomas, and discuss a clinical trial of the BCMA-CD3 bispecific antibody teclistamab in patients with relapsed/refractory multiple myeloma who have received previous BCMA-targeted therapy.Featured Articles:Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutationsRecurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissueEfficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

In this episode I talk about the recent PFL event that saw a return of Francis Ngannou to the MMA stage as well as Cris Cyborg making big MMA history. I also give some picks for UFC 308 Holloway vs Topuria. Hope you enjoy. Kru Luck Gym - www.LuckysMT.com Instagram - @Luckysmuaythai @Carreromartialarts --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including:3 bispecific antibodies approved for the treatment of R/R MM that target BCMA or GPRC5DThe role of bispecific antibodies in R/R MMSafety considerations for patients while receiving a bispecific antibodyEmerging data and clinical trials with bispecific antibodiesKey clinical pearls for optimal use of bispecific antibodiesPresenter:Caitlin Costello, MDClinical Professor of MedicineDirector, Multiple Myeloma ProgramDivision of Blood and Marrow TransplantationMoores Cancer CenterUC San DiegoLa Jolla, CaliforniaLink to full program: https://bit.ly/40bjFCZ

In this episode I talk about what went down between Khalil Roundtree jr. and Alex Pereira. What did Alex do that changed the way thre fight was going? Also, a little bit about the upcoming PFL Pay-per-view featuring the return of Francis Ngannou. Hope you enjoy. Peace, Kru Luck Gym - www.LuckysMT.com Instagram - @Luckysmuaythai @Carreromartialarts --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

In this episode I recap One Championship Denver Superlek vs Haggerty and I give my thoughts on UFC Noché at the Sphere in Vegas. Great fights for the last couple of weeks so heres my two cents. Enjoy, Kru Luck Gym - www.LuckysMT.com Insta - @Luckysmuaythai @Carreromartialarts --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

In a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Rahul Banerjee, MD, FACP, and Noopur Raje, MD, discussed the risk of secondary malignancies in patients with multiple myeloma who receive CAR T-cell therapy. Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center and an assistant professor in the Division of Hematology and Oncology at the University of Washington. Raje is the director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School. Banerjee and Raje spoke in the context of prior advisories from the FDA on the potential development of secondary T-cell malignancies in patients who receive CAR T-cell therapy for hematologic cancers. Specifically, the agency required a boxed warning for secondary T-cell malignancy risks for BCMA- or CD19-targeting therapies in April 2024.1 The conversation also touched upon reports of secondary malignancies in cases and trials such as CARTITUDE-1 (NCT04181827), in which second primary cancers were highlighted in 9 patients who received treatment with ciltacabtagene autoleucel (Carvykti).2 Considering these reports and warnings, Banerjee and Raje emphasized shared treatment decision-making with patients after assessing the risks and benefits of CAR T-cell therapy compared with other agents like bispecific antibodies. They also reviewed optimal strategies for monitoring and referring patients based on the incidence of certain toxicities. “[Treatment with] CAR T cells requires planning, and we need to have good control of the disease. We need to have 4 to 6 weeks of a lead time to get these effective treatments to our patients, so early referral is a good idea,” Raje said. “[For example], if you see chronic diarrhea in someone that is way out of the window of what you would expect, referring back to the CAR T-cell center is important so that we don't miss some of these toxicities.” References FDA requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. News release. FDA. April 18, 2024. Accessed August 22, 2024. https://tinyurl.com/5n8pm5ca San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. doi:10.1056/NEJMoa2303379

In a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Rahul Banerjee, MD, FACP, and Noopur Raje, MD, discussed the risk of secondary malignancies in patients with multiple myeloma who receive CAR T-cell therapy. Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center and an assistant professor in the Division of Hematology and Oncology at the University of Washington. Raje is the director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School. Banerjee and Raje spoke in the context of prior advisories from the FDA on the potential development of secondary T-cell malignancies in patients who receive CAR T-cell therapy for hematologic cancers. Specifically, the agency required a boxed warning for secondary T-cell malignancy risks for BCMA- or CD19-targeting therapies in April 2024.1 The conversation also touched upon reports of secondary malignancies in cases and trials such as CARTITUDE-1 (NCT04181827), in which second primary cancers were highlighted in 9 patients who received treatment with ciltacabtagene autoleucel (Carvykti).2  Considering these reports and warnings, Banerjee and Raje emphasized shared treatment decision-making with patients after assessing the risks and benefits of CAR T-cell therapy compared with other agents like bispecific antibodies. They also reviewed optimal strategies for monitoring and referring patients based on the incidence of certain toxicities. “[Treatment with] CAR T cells requires planning, and we need to have good control of the disease. We need to have 4 to 6 weeks of a lead time to get these effective treatments to our patients, so early referral is a good idea,” Raje said. “[For example], if you see chronic diarrhea in someone that is way out of the window of what you would expect, referring back to the CAR T-cell center is important so that we don't miss some of these toxicities.”  References 1. FDA requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. News release. FDA. April 18, 2024. Accessed August 22, 2024. https://tinyurl.com/5n8pm5ca  2. San-Miguel J, Dhakal B, Yong K, et al. CIlta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. doi:10.1056/NEJMoa2303379 

In this episode I rant about the things I thought went wrong for Israel Adesanya in his title fight with fellow African Dricus DuPlesis. I also go off about how good CJI was for BJJ and hwo Craig Jones is the face of Jiu Jitsu. Enjoy! Kru LuckGym - www.LuckysMT.com Insta - @Luckysmuaythai BJJ - @Carrerobjj --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

In this episode I talk about the Nate Diaz victory over Jorge Masvidal as well as Periera saving the UFC again. DDP faced off against Israel Adesanya and it was intense! Peave and blessings, Kru Luck --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

In this episode I recap some of Ufc Abu Dhabi as well as the end for Tony Ferguson maybe? Terence Crawford vs Madrimov fight. Does his performance mean no Canelo fight?? Enjoy, Kru Luck --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

Joe and Korey sit down with Ben Brusie, Arborist and Owner of Green Ridge Plant Care. Ben and the guys discuss his career and the importance of continuing to educate yourself as you move through your career. For more on Green Ridge Plant Care you can visit https://www.greenridgeplantcare.com/index.html If you enjoyed the podcast please rate, review, subscribe and tell a fellow tree lover! Send your questions or topics you would like us to discuss to ⁠info@discoveringforestrypodcast.com⁠. Be sure to follow us on all your favorite social media platforms! Twitter/X: @DisForestryPod Instagram: @discovering_forestry Facebook: Discovering Forestry YouTube: @discoveringforestry6905 LinkedIn: Discovering Forestry Podcast Music credit:⁠ Cool Tools Music Video - "Timber"⁠   ⁠Muzaproduction “Sport Rock Logo 1”⁠ Hosted by: Joe Aiken & Korey Lofy Produced by: Nico Manganiello Artwork by: Cara Markiewicz & Nico Manganiello --- Support this podcast: https://podcasters.spotify.com/pod/show/discoveringforestry/support

María-Victoria Mateos, MD, PhD - Updates in Multiple Myeloma From Madrid: Data Surrounding BCMA-Directed Agents and Their Clinical Relevance

María-Victoria Mateos, MD, PhD - Updates in Multiple Myeloma From Madrid: Data Surrounding BCMA-Directed Agents and Their Clinical Relevance

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

In this episode I talk about the big UFC 303 shake up, with Poatan and Jiri for the save. Gervonta takes out Frank Martin with a big KO. Was Silva vs Sonnen a work? Finally, is Israsel Adesanya back against DuPlessis for the title in Perth? A lot of questions and I do my best to weed through it all. Hope you enjoy. Peace and blessings, Kru Luck www.LuckysMT.com @luckysmuaythai @Carrerobjj --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

In this episode I rant on about so much happening in the fight world. Is Conor going to make the walk, Chael Sonnen finally gets a chance at redemption against Anderson Silva in the best way possible. Did Craig Jones just expose ADCC? so much happening. Hope you enjoy. Peace and Blessings Kru Luck Gym - www.LuckysMT.com @Luckysmuaythai BJJ - @Carrerobjj on Instagram --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/CAN865. CME/CPD credit will be available until 5 June 2025.Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/CAN865. CME/CPD credit will be available until 5 June 2025.Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/CAN865. CME/CPD credit will be available until 5 June 2025.Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/CAN865. CME/CPD credit will be available until 5 June 2025.Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/CAN865. CME/CPD credit will be available until 5 June 2025.Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

BCMA Ep. 89 I talk about Domestic Violence since the Puffy tape, Boxing is killing it right now. Also, Anderson Silva's announcement and my thoughts on that. Hope you enjoy. Peace and Blessings Kru Luck Gym - www.LuckysMT.com Instagram - @Luckysmuythai Carrero Jiu Jitsu - @Carrerobjj --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

Featuring an interview with Dr Joshua Richter, including the following topics: Management of cytokine release syndrome after bispecific antibody therapy; importance of clinical trials in the multiple myeloma (MM) treatment paradigm (0:00) Similarities and differences between and efficacy and tolerability of BCMA- and non-BCMA-directed bispecific antibodies in the treatment of MM (7:18) Case: A woman in her mid 60s with penta-refractory MM who achieves complete remission with linvoseltamab on a clinical trial (12:53) Case: A woman in her early 60s with multiregimen-refractory MM who experiences pain and tumor flare during step-up dosing of teclistamab (22:40) Case: A man in his late 60s with relapsed/refractory MM who experiences disease relapse 18 months after chimeric antigen receptor T-cell therapy begins treatment with talquetamab (28:34) Racial and ethnic disparities in the treatment of MM (32:09) CME information and select publications

Featuring a slide presentation and related discussion from Dr Joshua Richter, including the following topics: Similarities and differences between the cellular targets and mechanisms of action of BCMA- and non-BCMA-directed bispecific antibodies for multiple myeloma (MM) (0:00) Antitumor activity observed with teclistamab and elranatamab for relapsed/refractory MM (3:46) Published findings with investigational anti-BCMA bispecific antibodies such as linvoseltamab and alnuctamab for pretreated MM (12:40) Efficacy and safety of approved and investigational non-BCMA-targeted bispecific antibodies in patients with heavily pretreated MM (16:26) Early data with bispecific antibodies in combination with other systemic therapies for MM (22:55) Spectrum, incidence, severity and timing of cytokine release syndrome, neurotoxicity and other adverse events with BCMA- and non-BCMA-targeted bispecific antibodies (26:39) CME information and select publications

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.

Putting patients at center stage is at the core of John Crowley's vision for BIO as he begins his tenure leading the biotech trade group. On the latest BioCentury This Week podcast. Washington Editor Steve Usdin details Crowley's plans to revitalize BIO at a time when effective representation in Washington is more important than ever.BioCentury's editors also discuss FDA's landmark approval of Madrigal's liver disease drug and a decision by FDA's Oncologic Drugs Advisory Committee to support a pair of BCMA-directed CAR T cell therapies in earlier lines to treat multiple myeloma, and what's needed to help avoid deaths during the period while patient wait for the CAR T cells to be produced.